Abstract
The relative antimicrobial activity of a large series of semisynthetic coumermycins has been determined. Most of the derivatives, which were 3-substituted-4-hydroxy-8-methyl-7-[3-O-(5-methyl-2-pyrrolylcarbonyl) noviosyloxy] coumarins, had an in vitro antibacterial spectrum similar to that of the parent compound, coumermycin A1, but were generally less potent in minimal inhibitory concentration (MIC) tests. Derivatives with an alkylcarboxamido, arylcarboxamido, or arylsulfonamido group in the 3 position had considerably greater in vitro activity than those possessing an amino-, aryl-, or alkyureido substituent. Efficacy in Staphylcoccous aureus Smith infections of mice was greater for those compounds with branched-chain alkylcarboxamido, unsubstituted, mono- or disubstituted aryl- and heteroaryl-carboxamido groups than for derivatives having an n-alkylcarboxamido, aralkyl-carboxamido, arylsulfonamido, or trisubstituted arylcarboxamido substituent. Significant in vitro activity against Klebsiella pneumoniae and other gram-negative species was restricted to those compounds having a 3-(3-n-alkyl-4-hydroxy-phenyl-carboxamido) group. Only the n-hexyl homologue demonstrated in vivo activity in a K. pneumoniae infection. Many derivatives were two- to threefold more active than coumermycin A1 in orally treated mouse infections, despite the fact that their MIC values were considerably higher. This result was undoubtedly a reflection of the markedly greater oral absorbability possessed by many of the derivatives. Although peak oral mouse blood levels of some compounds were > 25 times higher than those of coumermycin A1, their toxicity for the host was no greater. In addition, the semisynthetic coumermycins caused much less local irritation than coumermycin A1 when administered parenterally.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- GOUREVITCH A., HUNT G. A., LUTTINGER J. R., CARMACK C. C., LEIN J. Activity of alpha-phenoxyalkyl penicillins against sensitive and resisant Staphylococci. Proc Soc Exp Biol Med. 1961 Jun;107:455–458. doi: 10.3181/00379727-107-26655. [DOI] [PubMed] [Google Scholar]
- KAWAGUCHI H., NAITO T., TSUKIURA H. STUDIES ON COUMERMYCIN. A NEW ANTIBIOTIC. II. STRUCTURE OF COUMERMYCIN A1. J Antibiot (Tokyo) 1965 Jan;18:11–25. [PubMed] [Google Scholar]
- KAWAGUCHI H., TSUKIURA H., OKANISHI M., MIYAKI T., OHMORI T., FUJISAWA K., KOSHIYAMA H. STUDIES ON COUMERMYCIN, A NEW ANTIBIOTIC. I. PRODUCTION, ISOLATION AND CHARACTERIZATION OF COUMERMYCIN A1. J Antibiot (Tokyo) 1965 Jan;18:1–10. [PubMed] [Google Scholar]
- Keil J. G., Hooper I. R., Cron M. J., Farbig O. B., Nettleton D. E. Semisynthetic coumermycins. I. Preparation of 3-acylamido-4-hydroxy-8-methyl-7-[3-O-(5-methyl-2-pyrrolylcarbonyl)noviosyloxy]coumarins. J Antibiot (Tokyo) 1968 Sep;21(9):551–566. [PubMed] [Google Scholar]
- Keil J. G., Hooper I. R., Cron M. J., Schmitz H., Nettleton D. E., Godfrey J. C. Preparation of semisynthetic coumermycin A1 derivatives. 3. Aromatic and heteroaromatic derivatives of 3-amino-4-hydroxy-8-methyl-7-[3-O-(5-methyl-2-pyrrolylcarbonyl) noviosyloxy]coumarin. Antimicrob Agents Chemother (Bethesda) 1968;8:120–127. [PubMed] [Google Scholar]
- Schmitz H., DeVault R. L., McDonnell C. D., Godfrey J. C. Semisynthetic coumermycins. II. Preparation and properties of 3-(substituted benzamido)-4-hydroxy-8-methyl-7-[3-O-(5-methyl-2-pyrrolylcarbonyl)noviosyloxy] coumarins. J Antibiot (Tokyo) 1968 Oct;21(10):603–610. [PubMed] [Google Scholar]
- WICK W. E., BONIECE W. S. IN VITRO AND IN VIVO LABORATORY EVALUATION OF CEPHALOGLYCIN AND CEPHALORIDINE. Appl Microbiol. 1965 Mar;13:248–253. doi: 10.1128/am.13.2.248-253.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]